登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
CRIC Combined With MFT for Cardiovascular Adverse Events in Patients With Incomplete Revascularization of CAD
ClinicalTrials.gov 上登记的一项冠心病开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06820970,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 4
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(4 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Heart failure patients with NYHA class IV, or left ventricular ejection fraction (LVEF) < 30%
排除标准第 2 条
Creatinine clearance <15 mL/min (or eGFR < 15 mL/min/1.73m²), or requires dialysis
排除标准第 3 条
Active liver disease or persistent ALT or AST elevation ≥ 3 times the upper limit of normal
排除标准第 7 条
History of active malignancy (surgery, radiation therapy, and/or systemic therapy within the past 3 years)
排除标准第 10 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;既往治疗;日常活动能力;影像与可测量病灶;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06820970,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
1) Age ≥18 years old 2) Consistent with the diagnosis of coronary heart disease, complete revascularization was not performed (coronary angiography showed that at least one vessel with a reference diameter of 3.0mm had stenosis greater than 90%, and quantitative flow ratio (QFR) < 0.80) 3) Symptoms of myocardial ischemia (resting or exertional angina; Angina allele: chest tightness, shortness of breath, etc.);排除标准:Exclusion Criteria:
Age < 18 years old Heart failure patients with NYHA class IV, or left ventricular ejection fraction (LVEF) < 30% Creatinine clearance <15 mL/min (or eGFR < 15 mL/min/1.73m²), or requires dialysis Myocardial diseases such as hypertrophic cardiomyopathy, dilated cardiomyopathy, etc. Uncontrolled or recurrent arrhythmic events (e.g., ventricular fibrillation, recurrent or symptomatic sustained ventricular tachycardia, complete heart block, atrial fibrillation with rapid ventricular rates, supraventricular tachycardia refractory to drugs) Poorly controlled hypertension (SBP > 180 mm Hg or DBP > 110 mm Hg) Active liver disease or persistent ALT or AST elevation ≥ 3 times the upper limit of normal Unexplained CK > 5 times the upper limit of normal, or elevated CK due to known muscle disease Planned or anticipated cardiac surgery or revascularization before randomization History of active malignancy (surgery, radiation therapy, and/or systemic therapy within the past 3 years) Diagnosed or suspected upper extremity vascular malformations, aneurysms, arteriovenous fistulas, or thrombosis Hearing impairment, unable to undergo mindfulness therapy Currently participating in another drug or device study, or within 30 days of completing another drug or device study or receiving another investigational drug Any life-threatening comorbid conditions expected to result in death within the next year (excluding cardiovascular diseases) Alcoholism, substance abuse history; and unwilling or unable to stop alcohol or substance abuse during the study History of major organ transplant (e.g., lung, liver, heart, bone marrow, kidney) Investigator's judgment of known major active and uncontrolled disease, or any medical, physical, or surgical conditions (e.g., infection, significant blood, kidney, metabolic, gastrointestinal, or endocrine dysfunction) that may interfere with participation in the clinical study As known to the investigator, the subject is unlikely to complete follow-up for more than 1 year or is expected to be unable to comply with the study requirements or understand the study's objectives and potential risks.
引自 ClinicalTrials.gov, NCT06820970, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06820970,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。